Searchable abstracts of presentations at key conferences in endocrinology

ea0011oc52 | Calcium and bone OC49 Novartis Oncology Young Investigator Award | ECE2006

In acromegaly bone mineral density depends on gonadal function

Kochman M , Zgliczynski W , Misiorowski W , Zdunowski P , Papierska L , Zgliczynski S

The aim of the study was to evaluate factors determining bone mineral density (BMD) and serum concentrations of osteocalcin (OC) and carboxyterminal telopeptide of type I collagen (ICTP) in acromegaly. Material consisted of 121 patients with active acromegaly, aged 23–80 years. In the whole group BMD, assessed by DXA, was: 0.35±0.15 at L2–L4, 0.60±0.11 at femoral neck, 0.05±0.12 at Ward’s triangle and 0.59±0.13 at trocha...

ea0029p171 | Bone & Osteoporosis | ICEECE2012

Denosumab increases BMD in primary hyperparathyroidism

Misiorowski W. , Zgliczynski W.

Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). An open-labeled, prospective trial was conducted to determine whether denosumab 60 mg subcutaneously given every 6 months, maintains or improves BMD in patients with PHPT.Six patients had symptomatic PHPT and met surgical guidelines however refused surgery, and twelve patients had mild PHPT, asymptomatic except low BMD. The primary outcome index, BMD, was meas...

ea0026p83 | Endocrine tumours and neoplasia | ECE2011

Effectiveness of zolendronic acid yearly for preventing bone loss in patients with neuroendocrine tumors on somatostatin analogue therapy

Zdunowski P , Misiorowski W , Zgliczynski W

Background: Neuroendocrine tumors awareness is developing. Carcinoid syndrome and hormonal overproduction may be controlled with somatostatin analogues in majority of cases. However, due to unspecific symptomatology in early stages of disease, majority of cases are diagnosed when process is disseminated. Co-morbidities and coexisting diseases are present in most of patients. Bone loss may be accelerated by metastizing tumor, peptides secreted or decreased absorption of vitamin...

ea0029p192 | Bone & Osteoporosis | ICEECE2012

Vitamin D status in patients treated with intravenous ibandronate: a cohort study

Papierska L. , Misiorowski W. , Rabijewski M. , Gietka-Czernel M.

In 100 consecutive osteoporotic women referred to our clinic we assessed 25OHD3 and PTH levels. Patients suffered from postmenopausal osteoporosis and intolerance of oral bisphosphonates, were treated at least for 6 months with calcium and vitamin D. The reasons of intolerance of oral medication were gastritis (53), esophagitis (18) or peptic ulcer (29 cases). Patients were therefore chronically treated with proton pump inhibitors (PPI). They were referred to our Clinic in ord...